MOTS-c vs Epithalon: Metabolic and Longevity Research

MOTS-c is an endogenous mitochondrial-derived peptide. The 2015 primary study identified a 16-amino-acid sequence within mitochondrial 12S rRNA and studied administered MOTS-c in mice. A plasma concentration, a laboratory peptide, and a clinical product are not interchangeable.

Epithalon, also called Epitalon or AEDG, is a defined synthetic tetrapeptide. FDA describes it as derived from the amino-acid composition of peptides in epithalamin, an extract originally obtained from bovine pineal gland. Epithalamin is a chemically different extract, not a synonym. Extract findings should not be assigned to Epithalon.[1][7][10]

In the foundational mouse study, MOTS-c treatment prevented age-related and high-fat-diet-induced insulin resistance and diet-induced obesity. The authors linked skeletal-muscle actions to folate-cycle and purine-biosynthesis effects with AMPK activation. These are administered-peptide results in mice, not a human metabolic outcome.

Human endogenous-biomarker evidence is narrower. In 10 lean and 10 obese adults, plasma MOTS-c did not differ between groups. Associations with HOMA and the Matsuda index remained only in lean participants. This small cross-sectional study cannot determine causation, validate a clinical biomarker, or predict administered-MOTS-c effects.[1][2]

ClinicalTrials.gov lists a completed, 88-participant phase 1a/1b study of the separately named investigational product CB4211 in healthy non-obese participants and participants with nonalcoholic fatty liver disease. It covers safety, pharmacokinetics, pharmacodynamics, and exploratory metabolic and liver-fat measures, but has no posted results. This trial cannot be treated as a human efficacy result for administered MOTS-c.

FDA’s 2026 compound-specific review reported that its literature search did not identify clinical studies evaluating administration of MOTS-c to human subjects. Endogenous plasma associations and administered-MOTS-c evidence must therefore remain separate.[3][9]

A 2003 experiment reported that adding Epithalon to telomerase-negative human fetal fibroblast culture induced hTERT expression, telomerase activity, and telomere elongation. These cell-culture findings do not measure clinical aging, cancer risk in patients, or lifespan.

Nonhuman longevity findings are mixed. A Drosophila study reported an 11 to 16 percent lifespan increase after developmental exposure. In a 54-per-group female-mouse study, Epitalon did not change mean lifespan, although maximum lifespan and survival in the final 10 percent were higher. Neither animal endpoint establishes a human longevity effect.[4][5][6]

FDA identified one small, short study of sublingual AEDG in women with low urinary 6-sulfatoxymelatonin, a melatonin metabolite. It reported biomarker and clock-gene measures, not sleep outcomes; FDA also noted unclear blinding and no established clinical applicability to insomnia. A ClinicalTrials.gov API search using Epitalon and Epithalon returned zero records, but does not rule out differently indexed or unregistered studies.

FDA states that compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality. In substance-specific reviews, FDA proposed against listing both MOTS-c and Epitalon bulk substances in the evaluated 503A process, citing gaps in human data and concerns about aggregation, impurities, and possible injection immunogenicity. These assessments do not show either peptide improves metabolism, sleep, aging, or lifespan.[8][9][10][11]